Sichuan Pudu

Sichuan Pudu Biopharmaceutical is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in developing oral agonists for incretin receptors, including GLP-1, GIP, and Glucagon receptors, aiming to provide more convenient alternatives to injectable peptide therapies. Their research primarily targets prevalent conditions such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). By leveraging their medicinal chemistry expertise, Sichuan Pudu aims to address significant unmet medical needs in the global metabolic health market.